Značaj adiponektina kao biomarkera metaboličkog sindroma i/ili koronarne bolesti

Sanja S Stojanović; Marina Deljanin Ilić; Stevan Ilić; Dejan Petrović; Svetlana Djukić

doi:10.2298/6189

Sanja S Stojanović Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia
Marina Deljanin Ilić Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia
Stevan Ilić Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia
Dejan Petrović Institut za lečenje i rehabilitaciju Niska Banja
Svetlana Djukić Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

DOI: https://doi.org/10.2298/6189

Ključne reči: adiponectin||, ||adiponektin, biological markers||, ||biološki pokazatelji, metabolic syndrome x||, ||metabolički sindrom x, coronary disease||, ||koronarna bolest,

Sažetak

Uvod/Cilj. Adiponektin ispoljava snažno zaštitno dejstvo u toku progresije insulinske rezistencije ili predijabetesa u ozbiljnije kliničke entitete, kao što su metabolički sindrom i/ili kardiovaskularne bolesti. Pošto hipoadiponektinemija doprinosi patofiziologiji metaboličkog sindroma i koronarne bolesti nivo cirkulišućeg adiponektina može biti rani marker kardiovaskularnih događaja. Cilj ove studije bio je da se utvrdi povezanost nivoa adiponektina i parametara insulinske rezistencije i gojaznosti kod bolesnika sa metaboličkim sindromom i/ili koronarnom bolešću, kao i da se proceni prediktivni značaj nivoa adiponektina kao biomarkera ovih entiteta. Metode. Studija je uključila 100 bolesnika sa metaboličkim sindromom i/ili koronarnom bolešću različitog stepena insulinske rezistencije i zdrave ispitanike sa normalnom glikoregulacijom. Nivo serumskog adiponektina, glukoze našte, insulinemije našte, HOMA-IR indeksa i antropometrijski parametri određivani su kod svih ispitanika. Adiponektin je meren korišćenjem ultrasenzitivnog ELISA metoda. Insulinemija je određivana radioimunoesej (RIA) metodom. Prisustvo glikemijskih poremećaja procenjeno je na osnovu testa oralne glukozne tolerancije (OGTT). Rezultati. Nivo adiponektina bio je u inverznoj korelaciji sa starošću i parametrima insulinske rezistencije i gojaznosti. Sniženja nivoa adiponektina bila su udružena sa rastućim stepenom insulinske rezistencije. Najvažnije, statistički značajan pad nivoa adiponektina bio je u stadijumu predijabetesa (p < 0,01). Prediktorska vrednost nivoa adiponektina iznosila je 1,356,32 ± 402,65 рg/mL. Zaključak. Dobijeni rezultati ukazuju na to da adiponektin može biti koristan marker u identifikaciji osoba sa povećanim rizikom od razvoja metaboličkog sindroma i koronarne bolesti, kao i prediktor predijabetesa.

Biografije autora

Sanja S Stojanović, Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia

doktor medicine Instituta Niska Banja, dokorat doktorskih studija medicine Univerziteta u Kragujevcu

Marina Deljanin Ilić, Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia

subspecijalista kardiolgije,

redovan profesor medicinskog fakulteta Niš

Stevan Ilić, Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia

Načelnik klinike za Kardiovaskularne bolesti Instituta Niska banja

Dekan Medicinskog fakultetaUniverziteta u Nišu

Dejan Petrović, Institut za lečenje i rehabilitaciju Niska Banja

Saradnik medicinskog famkulteta Nis
specijalista interne medicine Kliničkog Centra u Nisu

Specijalista interne medicine

Načelnik odeljenja specijalizovane rehabiitacije Instituta Niska Banja

Svetlana Djukić, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Saradnik medicinskog famkulteta Kragujevac
specijalista interne medicine Kliničkog Centra u Kragujevcu

Reference

Boydens C, Maenhaut N, Pauwels B, Decaluwé K, van de Voorde J. Adipose tissue as regulator of vascular tone. Curr Hypertens Rep 2012; 14(3): 270−8.

Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121(6): 2111−7.

Lago F, Gómez R, Gómez-Reino JJ, Dieguez C, Gualillo O. Adi-pokines as novel modulators of lipid metabolism. Trends Bio-chem Sci 2009; 34(10): 500−10.

Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316(2): 129−39.

Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, et al. Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. PLoS Genet 2012; 8(3): 1002607.

Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ, Black AE, . The genetic basis of plasma variation in adiponec-tin, a global endophenotype for obesity and the metabolic syndrome. J Clin Endocrinol Metab 2001; 86(9): 4321−5.

Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardio-vascular health: an update. Br J Pharmacol 2012; 165(3): 574−90.

Cheng KK, Lam KS, Wang B, Xu A. Signaling mechanisms un-derlying the insulin-sensitizing effects of adiponectin. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 3−13.

Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: les-sons from translational research. Am J Clin Nutr 2010; 91(1): 258−61.

Aronne LJ, Segal KR. Adiposity and Fat Distribution Outcome Measures: Assessment and Clinical Implications. Obes Res 2002; 10(1): 14−21.

World Health Organization. Definition, diagnosis and classifica-tion of diabetes mellitus and its complications, Part 1: Diagno-sis and classification of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance; 1999.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412−9.

Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, De Francisco A, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 2013; 13(1): 47.

RND sistems. Human Adiponectin/Acrp30 DuoSet. Available from: http://www.rndsystems.com/Products/DY1065.

Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148(5): 852−71.

Saely CH, Risch L, Hoefle G, Rein P, Muendlein A, Marte T, et al. Low serum adiponectin is independently associated with both the metabolic syndrome and angio-graphically determined coronary atherosclerosis. Clin Chim Acta 2007; 383(1−2): 97−102.

Luo S, Lei H, Liu Q. Correlation between serum adiponectin and risk factors in patients with coronary artery disease. Clin Lab 2013; 59(1−2): 121−6.

Oliveira GB, França JÍ, Piegas LS. Serum adiponectin and cardi-ometabolic risk in patients with acute coronary syndromes. Arq Bras Cardiol 2013; 101(5): 399−409.

Wang Y, Lam K , Yau M, Xu A. Post-translational modifica-tions of adiponectin: mechanisms and functional implications. Biochem J 2008; 409(3): 623−33.

Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, et. al. Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity ccording to the presence of diabetes mellitus: relation with inflammatory markers and adipokines. Cardiovasc Diabetol 2013; 12: 140.

Indulekha K, Surendar J, Anjana RM, Gokulakrishnan K, Bal-asubramanyam M, Aravindhan V, et al. Circulating levels of high molecular weight (HMW) adiponectin and total adiponectin in relation to fat distribution, oxidative stress and inflammation in Asian Indians. Dis Markers 2012; 33(4): 185−92.

Medina-Bravo P, Meza-Santibáñez R, Rosas-Fernández P, Galván-Duarte R, Saucedo-García R, Velázquez-López L, et al. Decrease in serum adiponectin levels associated with visceral fat accumula-tion independent of pubertal stage in children and adolescents. Arch Med Res 2011; 42(2): 115−21.

Hajer GR, van Haeften TW, Visseren F. Adipose tissue dysfunc-tion in obesity, diabetes and vascular diseases. Europ Heart J 2008; 29(24): 2959−71.

Trayhurn P, Bing C, Wood S. Adipose Tissue and Adipokines-Energy Regulation from the Human Perspective. J Nutr 2006; 136(7): 1935−9.

Shams M, Rasekhi Kazerouni A, Ostovan MA, Omrani GR. The re-lationship between serum adiponectin levels with the presence and severity of coronary artery disease. Arch Iran Med 2012; 15(10): 611−6.

Golubović MV, Dimić D, Antić S, Radenković S, Djindjić B, Jovanović M. Relationship of adipokine to insulin sensitivity and glycemic regulation in obese women - the effect of body weight reduction by caloric restriction. Vojnosanit Pregl 2013; 70(3): 284−91. (Serbian)

Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, et al. Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban Rural Epidemiol-ogy Study (CURES-4). Metabolism 2005; 54(4): 476−81.

Shahid A, Sager A, Muhammad FM, Syed DH, Kiran N, Muham-mad SH. Role of adiponectin as a biomarker of prediabetes. Med Channel 2012; 18(4): 72−5.